Advertisement
Clinical research study| Volume 129, ISSUE 2, P195-203, February 2016

Quality Improvement of Staphylococcus aureus Bacteremia Management and Predictors of Relapse-free Survival

Published:October 28, 2015DOI:https://doi.org/10.1016/j.amjmed.2015.09.016

      Abstract

      Purpose

      The purpose of this study is to improve the quality of care and patient outcomes for Staphylococcus aureus bacteremia.

      Methods

      A quasi-experimental pre- and postintervention study design was used to compare process and clinical endpoints before and after a quality-improvement initiative. All inpatients >18 years of age with a positive blood culture for S. aureus during the specified pre- and postintervention period with clinical information available in the electronic medical record were included. An institutional protocol for the care of patients with S. aureus bacteremia was developed, formalized, and distributed to providers using a pocket card, an electronic order set, and targeted lectures over a 9-month period.

      Results

      There were 167 episodes of S. aureus bacteremia (160 patients) identified in the preintervention period, and 127 episodes (123 patients) in the postintervention period. Guideline adherence improved in the postintervention period for usage of transesophageal echocardiogram (43.9% vs 20.2%, P <.01) and adequate duration of intravenous therapy (71% vs 60%, P = .05). In a multivariate Cox proportional hazard model, the variables associated with increased relapse-free survival were postintervention period (hazard ratio [HR] 0.48; confidence interval [CI], 0.24-0.95; P .035) and appropriate source control (HR 0.53; CI, 0.24-0.92; P .027). Regardless of intervention, presence of cancer was associated with an increased risk of relapse or mortality at 90 days (HR 2.88; P <.0001; CI, 1.35-5.01).

      Conclusion

      A bundled educational intervention to promote adherence to published guidelines for the treatment of S. aureus bacteremia resulted in a significant improvement in provider adherence to guidelines as well as increased 90-day relapse-free survival.

      Keywords

      Clinical Significance
      • A resident-run and trainee-focused educational initiative led to increased rates of transesophageal echocardiography and longer treatment duration for patients with Staphylococcus aureus bacteremia.
      • Improved adherence to guidelines led to a decrease in the relapse rate for S. aureus bacteremia.
      • This intervention was successful in a resource-limited hospital, and could be implemented in numerous other clinical settings.
      Staphylococcus aureus bacteremia is one of the most common causes of bloodstream infections worldwide and causes extensive morbidity and mortality, with death rates ranging from 20%-40%.
      • Wisplinghoff H.
      • Bischoff T.
      • Tallent S.M.
      • Seifert H.
      • Wenzel R.P.
      • Edmond M.B.
      Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.
      • Prowle J.R.
      • Echeverri J.E.
      • Ligabo E.V.
      • et al.
      Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality.
      • Kern W.V.
      Management of Staphylococcus aureus bacteremia and endocarditis: progresses and challenges.
      • Fowler Jr., V.G.
      • Olsen M.K.
      • Corey G.R.
      • et al.
      Clinical identifiers of complicated Staphylococcus aureus bacteremia.
      Numerous studies have demonstrated that treatment of S. aureus bacteremia in consultation with Infectious Disease specialty services or evidence-based bundled interventions can improve mortality rates.
      • Fries B.L.
      • Licitra C.
      • Crespo A.
      • et al.
      Infectious diseases consultation and the management of Staphylococcus aureus bacteremia.
      In this study, we present the results of a quality improvement initiative to improve management and outcomes of S. aureus bacteremia. This paper describes the process improvement methods and results, and also predictors of 90-day survival or freedom from relapse. Previous studies mostly used 30-day mortality as the primary clinical endpoint. Relapses of deep-seated infections often lead to readmissions, increased health care costs, and significant morbidity for patients. Given the propensity of S. aureus to relapse from deep sources if undertreated and prolonged effects on survival, 90-day freedom from relapse or survival may be a more meaningful marker of cure for S. aureus bacteremia.
      The objectives of this study were to 1) improve adherence to current guidelines for treatment of S. aureus bacteremia, and 2) to measure impact of improved adherence on survival and freedom from relapse at 90 days.

      Methods

      Setting, Intervention, and Design

      The intervention was performed at Parkland Memorial Hospital, a 784-bed public academic hospital in Dallas County, Texas, which averages 40,000 admissions annually. The facility serves as the main teaching hospital for the University of Texas Southwestern Medical Center. The patient population comprises largely uninsured minority patients with a large burden of HIV, diabetes, and end-stage renal disease.
      • Wilson K.S.
      • Eggleston E.
      • Diaz-Olavarrieta C.
      • Garcia S.G.
      HIV/STI risk among male Mexican immigrants in Dallas, Texas: findings from a pilot study.
      • Das S.R.
      • Vaeth P.A.
      • Stanek H.G.
      • de Lemos J.A.
      • Dobbins R.L.
      • McGuire D.K.
      Increased cardiovascular risk associated with diabetes in Dallas County.

      Parkland. Parkland by the numbers. Fiscal year 2014. Available at: http://www.parklandhospital.com/phhs/parklands-statistics.aspx. Accessed October 28, 2015.

      The study was designed as a resident-initiated and resident-run quality-improvement (QI) initiative with pre- and postintervention analysis. The effort was initiated and led by an Internal Medicine resident (JT) under faculty supervision (PS). The preintervention period was 1 year long, between October 1, 2010 and September 30, 2011. The intervention period was from December 2012 to September 2013. Postintervention data collection included the 6-month period from October 1, 2013 through March 28, 2014. The follow-up period ended June 28, 2014, giving a minimum of 90-day follow-up for postintervention cases. A timeline of the intervention is presented in Figure 1. Quality measures for the QI intervention were derived from published society guidelines, available at the time of study design, regarding treatment of S. aureus infections. Key definitions and treatment recommendations were extracted from the 2009 methicillin-resistant S. aureus (MRSA) treatment guidelines,
      • Liu C.
      • Bayer A.
      • Cosgrove S.E.
      • et al.
      Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
      the 2005 endocarditis guidelines from the American Heart Association,
      • Baddour L.M.
      • Wilson W.R.
      • Bayer A.S.
      • et al.
      Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.
      and the Infectious Diseases Society of America guidelines for treatment of catheter-related infections.
      • Mermel L.A.
      • Farr B.M.
      • Sherertz R.J.
      • et al.
      Guidelines for the management of intravascular catheter-related infections.
      The target measures were presented to the Infectious Disease Division for consensus review, and the Division endorsed them as the institutional standard of care for S. aureus bacteremia at Parkland. The Infectious Disease division's recommendations for universal transesophageal echocardiogram (TEE) in S. aureus bacteremia at Parkland were discussed at a noninvasive cardiology meeting and endorsed by the Division of Cardiology. Simplified recommendations regarding universal TEE, treatment duration by infection complexity, and first-line agents were compiled into an order set in the electronic medical record for treatment of S. aureus bacteremia as well as a pocket teaching card for house staff (Figure 2). A total of 160 surgical and medical house staff were given teaching cards. In addition, the primary author delivered 2 1-hour lectures on the treatment of S. aureus bacteremia to Internal Medicine residents (total 160 residents), a 5-minute talk to General Surgery residents (45 residents), and a 20-minute talk to the Cardiology Division (6 faculty, 3 fellows present), followed by distribution of teaching cards at the respective lectures. Twenty teaching cards were distributed in the Emergency Department during the intervention, although no formal talks were given to their staff.
      Figure thumbnail gr1
      Figure 1Project timeline for quality improvement initiatives for Staphylococcus aureus bacteremia, October 2010-March 2014.
      Figure thumbnail gr2
      Figure 2Pocket cards distributed to providers summarizing institutional protocol for Staphylococcus aureus bacteremia. Abx = antibiotic; AHA = American Heart Association; GIB = gastrointestinal bleed; IV = intravenous; MIC = minimum inhibitory concentration; MRSA = methicillin-resistant Staphylococcus aureus; MSSA = methicillin-susceptible Staphylococcus aureus; TEE = transesophageal echocardiogram.

      Data Collection

      All consecutive episodes of S. aureus bacteremia, defined as ≥1 positive blood culture during the preintervention period and the postintervention period, were identified from the blood culture reports of the Parkland Microbiology Laboratory. Patients were excluded if they were <18 years old, or had no clinical data available. The study was reviewed by the UT Southwestern Institutional Review Board and designated exempt as a QI project. Pre- and postintervention data collection through review of electronic medical records was done retrospectively at the end of the respective periods. Data including demographics, clinical features, treatment course, and outcomes of S. aureus bacteremia cases were reviewed by the primary author (JT) and ambiguities were adjudicated by the senior author (PS) when necessary. Confirmatory data on 90-day mortality were obtained by querying the Death Master file maintained by the Social Security Administration. Patients without follow-up data in the electronic medical record at 90 days were assumed to be free of relapse, as the majority of patients at the study institution return for follow-up care. Thirty-day follow-up records were available for all episodes of bacteremia, and 90-day follow-up records were available for 236/294 (80.3%) episodes.

      Definitions

      The primary process outcome assessed for guideline adherence was the number of patients undergoing TEE. Secondary process outcomes included median duration of antimicrobial treatment, time to appropriate antimicrobial treatment, follow-up blood cultures ordered, and source control measures performed during the initial admission. The primary clinical endpoint was relapse-free survival at 90 days from the date of initial positive blood culture. Relapse was defined as the return of signs or symptoms of a deep-seated and persistent staphylococcal infection, or development of new late complications (eg, endocarditis, osteomyelitis, recurrent S. aureus bacteremia) after a period of initial remission and hospital discharge. Relapse criteria included isolation of S. aureus with the same susceptibility pattern as the index episode, from the blood or other clinical specimen, recurrence of previous symptoms, or radiographic evidence of worsening at the site of the previous source.
      A body site was considered the source of S. aureus bacteremia if the symptoms at that site were present at the time of or preceding the bacteremia. Metastatic infections were defined as bacteremia episodes with evidence of embolic secondary foci, including radiographic evidence of septic emboli to the lungs, central nervous system, spinal column, or joints. If no source was apparent after the hospital workup, the source was classified as unknown. Endocarditis cases were diagnosed if the patient met or exceeded the definite category of the Modified Duke Criteria.
      • Li J.S.
      • Sexton D.J.
      • Mick N.
      • et al.
      Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.
      Infections were classified as community-onset if the patient had a positive blood culture for S. aureus or symptoms present within 72 hours of admission and no preceding health care contact. Patients with health care contact before admission (dialysis, hospitalization, nursing home residence, or home health care) with bacteremia in the first 72 hours were classified as “community-onset, health care-associated.” If the S. aureus bacteremia occurred after the patient had been hospitalized for 72 hours, the infection was considered hospital-onset. Bacteremia was considered uncomplicated if all of the following criteria were met: catheter-associated bloodstream infection with catheter removed, negative follow-up blood cultures drawn within 48-96 hours of initial positive blood culture, afebrile within 72 hours, no evidence of endocarditis on TEE (or transthoracic echocardiogram if no TEE was performed due to contraindications or low suspicion of endocarditis by treating physician), no indwelling prosthetic material, no evidence of deep or metastatic infection.
      • Liu C.
      • Bayer A.
      • Cosgrove S.E.
      • et al.
      Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
      • Mermel L.A.
      • Allon M.
      • Bouza E.
      • et al.
      Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America.
      For a complete list of criteria, see Table 1.
      • Fowler Jr., V.G.
      • Olsen M.K.
      • Corey G.R.
      • et al.
      Clinical identifiers of complicated Staphylococcus aureus bacteremia.
      Duration of bacteremia was defined as the time between the first positive blood culture and the first negative blood culture. A patient was considered to have undergone source control if they had complete drainage of an abscess, catheter removal, valve replacement, or removal of infected hardware. In the case of an early prosthetic joint infection, if the patient underwent a washout of the infected space, source control was considered to be adequate. In the case of a spinal hardware infection, if the patient underwent complete drainage of the involved site, but the hardware was retained for spinal stability, source control was considered adequate.
      Table 1Criteria for Complicated Bacteremia
      • Follow-up blood cultures positive between 48 and 96 h
      • Febrile beyond 72 h of initial blood culture
      • Endovascular infection
        •  Evidence of endocarditis on TTE or TEE, or both
        •  Septic thrombophlebitis
      • Indwelling prosthetic device
        •  Intracardiac device
        •  Prosthetic joint
        •  Ureteral stent
        •  Endovascular graft
        •  Abdominal mesh at site of infection
        •  Indwelling vascular catheter
      • Complicated pneumonia
        •  Loculated pleural effusions
        •  Cavitary lesions
        •  Empyema requiring drainage
        •  Prolonged intubation >48 h
        •  Prolonged shock >48 h
      • Complicated skin and soft tissue infection
        •  Phlegmon or undrained abscess
        •  Myositis
      • Metastatic infection at a secondary site
      • Unamputated osteomyelitis
      • Pericarditis
      • Mediastinitis
      • Endophthalmitis
      • Meningitis
      TEE = transesophageal echocardiogram; TTE = transthoracic echocardiogram.
      Both empiric and definitive treatment regimens were recorded, including antibiotic name, route, time to administration from positive blood culture, total duration, and total intravenous duration. Regimens were classified as first-line, acceptable, or inappropriate as follows for methicillin-susceptible S. aureus: first-line (nafcillin or cefazolin), acceptable (ceftriaxone, piperacillin/tazobactam, clindamycin, cefepime), inappropriate (vancomycin and all others). Classification for MRSA was as follows: first-line (vancomycin), acceptable (clindamycin, daptomycin, linezolid, ceftaroline), inappropriate (all others). Treatment duration was considered to be appropriate if ≥14 days in uncomplicated cases, and ≥28 days in complicated cases. The number of patients seen by the Infectious Disease consult service and the outpatient parenteral antibiotic therapy (OPAT) clinic were also recorded.

      Statistical Analysis

      Clinical features of S. aureus bacteremia, overall relapse rate, readmission rate, and source of infection were reported for each unique S. aureus bacteremia episode (n = 294). Demographics and mortality figures were calculated for unique patients (n = 283). Guideline adherence measures were calculated for each unique episode, excluding cases in which the patient died before blood culture results were available to providers (within 48 hours of blood cultures) (n = 286). Candidate predictor variables for freedom from recurrence and survival were selected based on clinical judgment and published literature.
      • Fowler Jr., V.G.
      • Olsen M.K.
      • Corey G.R.
      • et al.
      Clinical identifiers of complicated Staphylococcus aureus bacteremia.
      • Khatib R.
      • Sharma M.
      Echocardiography is dispensable in uncomplicated Staphylococcus aureus bacteremia.
      • Chang F.Y.
      • MacDonald B.B.
      • Peacock Jr., J.E.
      • et al.
      A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance.
      • Li Y.
      • Friedman J.Y.
      • O'Neal B.F.
      • et al.
      Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients.
      Comparisons between pre-and postintervention demographics, guideline adherence measures, and outcomes were done using chi-squared test or Fisher's exact test, as appropriate.
      Kaplan-Meier curves were generated in Stata 13, and univariate comparisons were made using log-rank tests.
      StataCorp
      Stata: Release 13.
      Stata 13 was used to build the Cox proportional hazards multivariate model. Forward selection using the Akaike Information Criteria (AIC) was used to select covariates that would build a model that best fit the data and were parsimonious. AIC was evaluated for a decrease in value after each new variable was added to the model. Once the AIC value increased, it then became unnecessary to add additional variables to the model.

      Results

      A total of 167 eligible episodes of S. aureus bacteremia (in 160 patients) were identified in the preintervention period, and 127 episodes (in 123 patients) in the postintervention period, for a total of 294 episodes of S. aureus bacteremia in 283 unique patients. Age, race, and comorbid conditions were not significantly different between these groups (Table 2), with a large percentage being male, non-White ethnicity, and diabetic. Clinical features were similar in the postintervention group compared with preintervention, with the exceptions of immunosuppression (10% vs 4.4%, P .01), MRSA (33.9% vs 52.7%, P <.01), and unknown source (10.2% vs 4.2%, P .04). Over 80% (242/294) of cases were community-onset, and 150/242 (62%) of the community-onset infections were health care associated. A majority of the bacteremias (54.5% preintervention and 59.8% postintervention) were complicated. The percentage of patients diagnosed with endocarditis rose significantly from 3.0% preintervention to 13.4% postintervention (P <.01), while other sources remained stable.
      Table 2Comparison of Demographics, Clinical Features, and Outcomes of SAB Episodes Pre- and Postintervention
      Preintervention n (%)Postintervention n (%)P-Value
      Demographics of patients (n = 283)(n = 160)(n = 123)
       Male103 (64.4)82 (66.7).31
       Age, y: median (IQR)52 (41-58)52 (42-60).91
       Hispanic ethnicity49 (30.6)50 (40.7).04
      P-values considered significant if <.05.
      Past medical history
       Diabetes mellitus64 (40)54 (43.9).28
       End-stage renal disease24 (15.0)24 (19.5).25
       Malignancy20 (12.5)19 (15.4).39
       Cirrhosis20 (12.5)11 (8.9).19
       Steroids or immunosuppression7 (4.4)13 (10.6).01
      P-values considered significant if <.05.
       Indwelling hardware13 (8.1)11 (8.9).45
       HIV11 (6.9)7 (5.7).48
      Clinical features of all SAB episodes (n = 294)(n = 167)(n = 127)
       Number of positive blood cultures per admission (mean, range)2 (1-11)3 (1-12).06
       Patients with positive follow-up blood cultures at 48-96 h15 (9.0)27 (21.3)<.001
      P-values considered significant if <.05.
       Time to blood culture clearance (hours)61.42 (39-92)67.25 (36-99).61
       Fever >72 h8 (4.8)4 (3.1).56
       MRSA88 (52.7)43 (33.9)<.001
      P-values considered significant if <.05.
      Epidemiology
       Hospital-onset SAB29 (17.4)23 (18.1).87
       Community-acquired SAB50 (29.9)40 (31.5).77
       Community-onset – health care-associated88 (52.7)64 (50.4).70
       Complicated bacteremia91 (54.5)76 (59.8).36
       Metastatic at onset23 (13.8)19 (15.0).77
      Source
       Bone and joint40 (24.0)27 (21.3).59
       Catheter30 (18.0)32 (25.2).13
       Skin and soft tissue40 (24.0)21 (16.5).12
       Respiratory32 (19.2)19 (15.0).35
       Unknown7 (4.2)13 (10.2).04
      P-values considered significant if <.05.
       Endocarditis (primary and secondary)5 (3.0)17 (13.4).60
       Urinary7 (4.2)7 (5.5).60
       Other8 (6.3)2 (1.2).39
      Outcomes by patient (n = 283)(n = 160)(n = 123)
       Overall 30-day mortality14 (8.8)9 (7.3).66
      Complicated bacteremia (n = 91 pre, n = 76 post)4 (4.4)6 (7.9).51
      Uncomplicated bacteremia (n = 32 pre, n = 66 post)10 (31.3)3 (4.5).24
       Overall 90-day mortality20 (12.5)15 (12.2).94
      Outcomes by episode (n = 294)(n = 167)(n = 127)
       Length of hospital stay (d, median, IQR)14 (7-26)13 (8-21).68
       Length of ICU stay (d, mean, range)3.1 (0-58)5.3 (0-211).25
       30-day readmission, n (%)49 (30.6)25 (20.3).06
      Complicated bacteremia29 (31.9)9 (11.8)<.001
      P-values considered significant if <.05.
      Uncomplicated bacteremia16 (50.0)20 (30.3).54
       Relapse within 90 d19 (11.9)3 (2.4)<.001
      P-values considered significant if <.05.
      Complicated bacteremia17 (18.7)3 (3.9)<.001
      P-values considered significant if <.05.
      Uncomplicated bacteremia2 (6.3)0 (0.0).52
      Data are presented as no. (%) unless otherwise specified.
      HIV = human immunodeficiency virus; ICU = intensive care unit; IQR = interquartile range; MRSA = methicillin-resistant Staphylococcus aureus; MSSA = methicillin-susceptible Staphylococcus aureus; SAB = Staphylococcus aureus bacteremia.
      P-values considered significant if <.05.
      Comparison of outcomes pre- and postintervention is shown in Table 2. All-cause mortality was not significantly different pre- and postintervention (8.1% vs 7.7% at 30 days, P = .66). The rate of relapse at 90 days dropped in the postintervention period, from 11.9% to 2.4% (P <.01), which was most marked for patients with complicated bacteremia. In the uncomplicated group, 2 patients relapsed at 90 days, neither of which had a TEE. The 30-day readmission rate for complicated bacteremia also improved significantly postintervention.
      In the multivariate Cox proportional hazard model, the variables associated with increased relapse-free survival were postintervention period (hazard ratio [HR] 0.48; confidence interval [CI], 0.24-0.95; P .035) and appropriate source control (HR 0.53; CI, 0.24-0.92; P .027) (Table 3). The following variables were entered into the multivariate model: cancer, postintervention, source control, source of infection, and duration of intravenous (IV) therapy. Source of infection and adequate duration of IV therapy were not significantly associated with a decrease in the endpoint when controlling for the other variables. The Kaplan-Meier survival curves showing the difference in relapse-free survival pre- and postintervention are shown in Figure 3.
      Table 3Multivariate Cox Proportional Hazards Models for Predictors of Combined 90-day Mortality and Relapse
      Adjusted Hazard RatioConfidence IntervalsP-Value
      90-day mortality or relapse (n = 294)
      Model adjusted for source of infection and duration of intravenous antibiotic treatment in addition to the variables shown.
       Cancer2.881.35-5.01.004
      P-values considered significant if <.05.
       Source control0.530.24-0.92.027
      P-values considered significant if <.05.
       Post intervention0.480.24-0.95.035
      P-values considered significant if <.05.
      Model adjusted for source of infection and duration of intravenous antibiotic treatment in addition to the variables shown.
      P-values considered significant if <.05.
      Figure thumbnail gr3
      Figure 3Impact of intervention on combined 90-day relapse or mortality. Time to event curve, univariate Cox proportional hazard model.
      Adherence to target guidelines increased in the postintervention period. Changes in adherence to guideline measures in the postintervention period are presented in Table 4. The most significant changes were an increase in the number of TEEs performed within 14 days of S. aureus bacteremia (from 20.2% to 43.9%, P = .001), a decrease in the time to appropriate antibiotic therapy (5.0 hours to 0.9 hours, P <.001), and an increase in the average duration of IV therapy from 18 days to 21 days (P = .001). In the group with complicated infections, 38/73 patients (52%) underwent TEE in the postintervention period, compared with 24/90 (26.7%) preintervention. The percentage of echocardiograms performed overall (82.3% of episodes) and TEEs performed for complicated patients (54.3%) in the postintervention period are among the highest reported.
      • Khatib R.
      • Sharma M.
      Echocardiography is dispensable in uncomplicated Staphylococcus aureus bacteremia.
      • Kaasch A.J.
      • Fowler Jr., V.G.
      • Rieg S.
      • et al.
      Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia.
      Over 70% of the patients in the postintervention period received an adequate duration of IV therapy, with a median of 38 days in complicated cases. The median duration of IV therapy increased in the postintervention period from 28 to 38 days (P = .037) for complicated infections, and from 15 to 16 days for uncomplicated infections (P >.05). The order set was used in 16/123 episodes (13%) in the postintervention period.
      Table 4Comparison of Adherence to Recommended SAB Management Process Measures Pre- and Postintervention
      Process Endpoints by Episode
      Excluding patients who died in <48 hours, before providers aware of blood culture results.
      (n = 286)
      Preintervention

      n = 163

      n (%)
      Postintervention

      n = 123

      n (%)
      95% CIP-Value
      Order set usage0 (0)16 (13)5.2-1022<.001
      P-values considered significant if <.05.
      Surveillance blood cultures at 48-96 h127 (77.9)102 (82.9)0.75-2.50.290
      Transthoracic echocardiogram performed133 (81.6)104 (84.6)0.66-2.32.510
      Transesophageal echocardiogram performed33 (20.2)54 (43.9)1.83-5.20<.001
      P-values considered significant if <.05.
       Complicated bacteremia24 (26.7)38 (54.3)1.55-5.75<.001
      P-values considered significant if <.05.
       Uncomplicated bacteremia9 (12.3)16 (30.2)1.34-8.37.008
      P-values considered significant if <.05.
      Adequate empiric therapy
      Administration of active drug based on sensitivities within 12 hours of blood culture.
      109 (66.9)99 (80.5)1.20-3.55.01
      P-values considered significant if <.05.
      Source control done (if indicated)
      Presence of a deep focus of infection, such as abscess, catheter, device, prosthetic joint.
      145 (91.8)73 (83.9)0.1-1.05.060
      Use of recommended agent for definitive treatment
      Vancomycin (methicillin-resistant Staphylococcus aureus) or nafcillin/cefazolin (methicillin-susceptible Staphylococcus aureus) used for >50% of treatment course.
      111 (68.1)89 (72.3)0.71-2.01.510
      Adequate duration of IV therapy
      For uncomplicated infection ≥14 days IV therapy, for complicated infections ≥28 days IV therapy with an active agent.
      96 (60.0)87 (71.3)1.001-2.74.049
      Model adjusted for source of infection and duration of intravenous antibiotic treatment in addition to the variables shown.
      Hours to appropriate antibiotic (median, IQR)5.0 (1-16)0.9 (1.0-4.0)-<.001
      Model adjusted for source of infection and duration of intravenous antibiotic treatment in addition to the variables shown.
      Inpatient IV duration (median, IQR)13(6-18)10.5 (6.2-16.6)-<.001
      Model adjusted for source of infection and duration of intravenous antibiotic treatment in addition to the variables shown.
       Complicated bacteremia (median, IQR)14 (8-22)12.4 (8.2-21.5)-NS
       Uncomplicated bacteremia (median, IQR)9.0 (4.3-13.9)8 (5.0-15.0)-NS
      Outpatient IV duration (median, IQR)1.0 (0.0-14.0)9.9 (0.8-22.8)-NS
       Complicated bacteremia (median, IQR)6.0 (0.0-25.0)17.0 (1.9-28.8)-<.001
      P-values considered significant if <.05.
       Uncomplicated bacteremia (median, IQR)0.0 (0.0-9.0)6.0 (0.4-11.8)-.033
      P-values considered significant if <.05.
      Total IV duration (median, IQR)18 (14-35)21 (15-43)-.001
      P-values considered significant if <.05.
       Complicated bacteremia (median, IQR)28 (16-46)38 (20-47)-.037
      P-values considered significant if <.05.
       Uncomplicated bacteremia (median, IQR)15 (11-18)16 (14-20)-NS
      Total duration (IV and PO) (median, IQR)19 (14-35)23 (16-44)-NS
       Complicated bacteremia (median, IQR)28 (17-47)41 (20-49)-.037
      P-values considered significant if <.05.
       Uncomplicated bacteremia (median, IQR)16 (13.5-19.0)16 (14-20)-NS
      Infectious disease consultation58 (35.6)65 (52.8).005
      P-values considered significant if <.05.
      Outpatient parenteral antibiotic clinic referral30 (18.4)56 (45.5)<.001
      P-values considered significant if <.05.
      Oral antibiotics only18 (11.0)6 (4.9)0.93-5.53.080
      Inappropriate antibiotic days (mean, range)3.0 (0-28)2.6 (0-45)-NS
      Data are presented as No. (row %) unless otherwise specified.
      IQR = interquartile range; IV = intravenous; NS = nonsignificant; PO = per os (by mouth).
      P-values considered significant if <.05.
      Excluding patients who died in <48 hours, before providers aware of blood culture results.
      Administration of active drug based on sensitivities within 12 hours of blood culture.
      § Presence of a deep focus of infection, such as abscess, catheter, device, prosthetic joint.
      Vancomycin (methicillin-resistant Staphylococcus aureus) or nafcillin/cefazolin (methicillin-susceptible Staphylococcus aureus) used for >50% of treatment course.
      For uncomplicated infection ≥14 days IV therapy, for complicated infections ≥28 days IV therapy with an active agent.

      Discussion

      Our study demonstrates the ability of a resident-initiated and resident-run QI initiative to improve management and outcomes of patients with staphylococcal bacteremia. A striking finding of our study was that a relatively modest intervention resulted in a significant change in hospital-wide treatment of S. aureus bacteremia. QI interventions in teaching hospitals have the potential to be successful due to close peer relationships through which high-yield education is multiplied internally. If well engrained in one generation of residents, patterns of practice have the potential to perpetuate year after year in a training program in a way that is not possible among independently practicing physicians. The uptake of the order set was poor and was likely not a significant contributor to guideline adherence. Because this intervention succeeded in a resource-limited safety-net hospital, this intervention strategy may be generalizable to other academic medical centers as well.
      The success of the intervention may also have stemmed from the fact that we targeted not only provider education, but also institutional barriers to consistent guideline adherence. A key ingredient of the intervention's impact was the development of an institutional standard of care through multidisciplinary consensus. Successful treatment of S. aureus bacteremia often requires assistance from multiple specialties, including Cardiology, Surgery, Infectious Disease, and outpatient services (OPAT Clinic). During the study period, the conversations between study staff and the above-mentioned parties helped to reduce variations in practice that are a common source of frustration for trainees as well as patients.
      While previous bundles have relied on sporadic or mandatory Infectious Disease consultations,
      • Lopez-Cortes L.E.
      • Del Toro M.D.
      • Galvez-Acebal J.
      • et al.
      Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia.
      the present intervention was designed to equip a large segment of providers to manage this common infection according to guidelines. While the number of patients with Infectious Disease consultations increased substantially in the postintervention period, this was not an independent predictor of clinical success in the multivariate model. Similarly, the number of patients referred to the OPAT specialty clinic also increased, but this did independently predict success when adjusting for the other elements of the intervention. In short, the impact of the intervention was greater than the sum of its parts.
      Our study was limited by being a single-center intervention with a smaller sample size than other studies conducted for S. aureus bacteremia. We found a very low baseline mortality rate despite a high level of comorbid illness, approaching the lower limits of what has been reported for S. aureus bacteremia.
      • Roder B.L.
      • Wandall D.A.
      • Frimodt-Moller N.
      • Espersen F.
      • Skinhoj P.
      • Rosdahl V.T.
      Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark.
      • Cosgrove S.E.
      • Sakoulas G.
      • Perencevich E.N.
      • Schwaber M.J.
      • Karchmer A.W.
      • Carmeli Y.
      Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.
      • Asgeirsson H.
      • Gudlaugsson O.
      • Kristinsson K.G.
      • Heiddal S.
      • Kristjansson M.
      Staphylococcus aureus bacteraemia in Iceland, 1995-2008: changing incidence and mortality.
      We speculate that the mortality may be low in our study group due to a low mean age, the large number of blood cultures done in uncomplicated skin and soft tissue infections, and around-the-clock availability of multiple subspecialty services to assist with source control measures. We acknowledge that there may be unmeasured (eg, factors affecting community incidence of S. aureus bacteremia and factors affecting the proportion of methicillin resistance in our study population) variables that may have served as confounding factors and influenced the outcomes in our study.

      Conclusion

      While Saureus bacteremia remains a common and dangerous infection across the nation and the world, evidence is growing that regular adherence to evidence-based guidelines can have a positive impact on patient outcomes. Health care systems should equip providers with the knowledge of current guidelines and remove systemic barriers to adherence when they arise.

      Acknowledgment

      We thank Kelly Smith, MS (Parkland Department of Information Technology) for assistance with order set build in the electronic medical records; Kavita Bhavan, MD (University of Texas Southwestern Division of Infectious Disease) for support and ideas; Roger Bedimo, MD for advice and manuscript review; Khalil Ghanem for statistical and editorial help; and the Dallas-Fort Worth Hospital Council Foundation for access to the Death Master Database.

      References

        • Wisplinghoff H.
        • Bischoff T.
        • Tallent S.M.
        • Seifert H.
        • Wenzel R.P.
        • Edmond M.B.
        Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.
        Clin Infect Dis. 2004; 39: 309-317
        • Prowle J.R.
        • Echeverri J.E.
        • Ligabo E.V.
        • et al.
        Acquired bloodstream infection in the intensive care unit: incidence and attributable mortality.
        Crit Care. 2011; 15: R100
        • Kern W.V.
        Management of Staphylococcus aureus bacteremia and endocarditis: progresses and challenges.
        Curr Opin Infect Dis. 2010; 23: 346-358
        • Fowler Jr., V.G.
        • Olsen M.K.
        • Corey G.R.
        • et al.
        Clinical identifiers of complicated Staphylococcus aureus bacteremia.
        Arch Intern Med. 2003; 163: 2066-2072
        • Fries B.L.
        • Licitra C.
        • Crespo A.
        • et al.
        Infectious diseases consultation and the management of Staphylococcus aureus bacteremia.
        Clin Infect Dis. 2014; 58: 598-599
        • Wilson K.S.
        • Eggleston E.
        • Diaz-Olavarrieta C.
        • Garcia S.G.
        HIV/STI risk among male Mexican immigrants in Dallas, Texas: findings from a pilot study.
        J Immigr Minor Health. 2010; 12: 947-951
        • Das S.R.
        • Vaeth P.A.
        • Stanek H.G.
        • de Lemos J.A.
        • Dobbins R.L.
        • McGuire D.K.
        Increased cardiovascular risk associated with diabetes in Dallas County.
        Am Heart J. 2006; 151: 1087-1093
      1. Parkland. Parkland by the numbers. Fiscal year 2014. Available at: http://www.parklandhospital.com/phhs/parklands-statistics.aspx. Accessed October 28, 2015.

        • Liu C.
        • Bayer A.
        • Cosgrove S.E.
        • et al.
        Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
        Clin Infect Dis. 2011; 52: e18-e55
        • Baddour L.M.
        • Wilson W.R.
        • Bayer A.S.
        • et al.
        Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America.
        Circulation. 2005; 111: e394-e434
        • Mermel L.A.
        • Farr B.M.
        • Sherertz R.J.
        • et al.
        Guidelines for the management of intravascular catheter-related infections.
        Clin Infect Dis. 2001; 32: 1249-1272
        • Li J.S.
        • Sexton D.J.
        • Mick N.
        • et al.
        Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis.
        Clin Infect Dis. 2000; 30: 633-638
        • Mermel L.A.
        • Allon M.
        • Bouza E.
        • et al.
        Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America.
        Clin Infect Dis. 2009; 49: 1-45
        • Khatib R.
        • Sharma M.
        Echocardiography is dispensable in uncomplicated Staphylococcus aureus bacteremia.
        Medicine. 2013; 92: 182-188
        • Chang F.Y.
        • MacDonald B.B.
        • Peacock Jr., J.E.
        • et al.
        A prospective multicenter study of Staphylococcus aureus bacteremia: incidence of endocarditis, risk factors for mortality, and clinical impact of methicillin resistance.
        Medicine. 2003; 82: 322-332
        • Li Y.
        • Friedman J.Y.
        • O'Neal B.F.
        • et al.
        Outcomes of Staphylococcus aureus infection in hemodialysis-dependent patients.
        Clin J Am Soc Nephrol. 2009; 4: 428-434
        • StataCorp
        Stata: Release 13.
        StataCorp LP, College Station, TX2013
        • Kaasch A.J.
        • Fowler Jr., V.G.
        • Rieg S.
        • et al.
        Use of a simple criteria set for guiding echocardiography in nosocomial Staphylococcus aureus bacteremia.
        Clin Infect Dis. 2011; 53: 1-9
        • Lopez-Cortes L.E.
        • Del Toro M.D.
        • Galvez-Acebal J.
        • et al.
        Impact of an evidence-based bundle intervention in the quality-of-care management and outcome of Staphylococcus aureus bacteremia.
        Clin Infect Dis. 2013; 57: 1225-1233
        • Roder B.L.
        • Wandall D.A.
        • Frimodt-Moller N.
        • Espersen F.
        • Skinhoj P.
        • Rosdahl V.T.
        Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark.
        Arch Intern Med. 1999; 159: 462-469
        • Cosgrove S.E.
        • Sakoulas G.
        • Perencevich E.N.
        • Schwaber M.J.
        • Karchmer A.W.
        • Carmeli Y.
        Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis.
        Clin Infect Dis. 2003; 36: 53-59
        • Asgeirsson H.
        • Gudlaugsson O.
        • Kristinsson K.G.
        • Heiddal S.
        • Kristjansson M.
        Staphylococcus aureus bacteraemia in Iceland, 1995-2008: changing incidence and mortality.
        Clin Microbiol Infect. 2011; 17: 513-518